News

Latest news
October 11, 2026

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and...

October 07, 2026

Temab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors including...

October 05, 2026

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival...

More »

AbbVie on

Looking for more news from AbbVie? Follow us on social media.

News

Advanced Search
Show 5102550100 per page
Who we are

Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more

Sustainability

Our commitment to science is a commitment to better our society. Read our 2025 ESG report

Key Facts

Get a closer look at our impact. 
Learn more

Annual report

See our latest 2025 Annual Report on Form 10-K. Learn more

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?